Luma Vision announced that it completed 15 AFib ablation procedures as part of a clinical study in collaboration with CardioFocus.
LUMA Vision Ltd., a leader in cardiac 4D navigation and imaging, today announced the successful completion of 15 VERAFEYE™-guided persistent atrial fibrillation (AF) ablation procedures conducted as ...
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation Pulse Biosciences, Inc. (Nasdaq: PLSE), a company ...
Long-term efficacy following cryoballoon ablation of lone paroxysmal atrial fibrillation remains unknown. We describe long-term follow-up results of the single cryoballoon ablation procedure. Methods ...
Cryoballoon pulmonary vein isolation has become an established treatment for atrial fibrillation (AF). However, data on long-term outcomes beyond 5 years are scarce. This prospective analysis aimed to ...
Background: The achievement of first-pass isolation (FPI) during pulmonary vein isolation (PVI) generally serves as a reliable marker of lesion quality in initial radiofrequency encirclement and ...
QuickShot Nav Delivers Versatile Map-and-Ablate Performance in the Quick AF Trial MARLBOROUGH, Mass.--(BUSINESS WIRE)--#AFib--CardioFocus, Inc., a medical device company dedicated to advancing ...
The View Hospital, in affiliation with Cedars-Sinai, has announced a groundbreaking achievement, having successfully performed the first Pulmonary Vein Isolation procedure and the first ...
Just months after FDA approval, Johnson & Johnson paused the rollout of its Varipulse pulsed field ablation (PFA) platform in the U.S. due to safety reasons. In a U.S. external evaluation cohort, four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback